Postoperative Analgesic Effect Of Dexmedetomidine Administration in Wound Infiltration for Total Abdominal Hysterectomy

Phase 4 Study of Postoperative Analgesic Effect Of Dexmedetomidine Administration in Wound Infiltration For Total Abdominal Hysterectomy

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01929252

Enrollment

Registered

2013-08-27

Start date

2011-08-31

Completion date

2012-08-31

Last updated

2013-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Keywords

dexmedetomidine, wound infiltration, postoperative analgesia

Brief summary

The aim of this study was to investigate the analgesic efficacy of dexmedetomidine administration in wound infiltration for total abdominal hysterectomy.

Detailed description

Abdominal hysterectomy is associated with moderate to severe postoperative pain, effective analgesia after hysterectomy essential and several techniques are used such as administration of opioids, nonsteroidal anti-inflammatory drugs and wound infiltration of local anaesthetics. Different local anaesthetics can be used for the wound infiltration techniques.Ifiltration of the surgical wound with bupivacaine following outpatient provides pain relief in the postoperative period , allows the early discharge from the outpatient surgical units.There has been increased interest in administration of analgesic prior to surgical injury. Dexmedetomidine is a highly selective alpha-2 adrenergic agonist with sedative , anxiolytic, analgesic, sympatholytic and antihypertensive effects.Dexmedetomidine has been used intravenously before initiation of anaesthesia and it has shown to provide some analgesic effect after surgery but there were some adverse hemodynamic effects. Surgical wound administration of dexmedetomidine may be useful to avoid the adverse haemodynamic effects of intravenous administration while still providing the postoperative analgesia.

Interventions

DRUGDexmedetomidine

2mcg.kg-1 dexmedetomidine wound infiltration

DRUGLevobupivacaine

0.25% levobupivacaine (40ml) wound infiltration

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* 18-65 yo female * scheduled for elective hysterectomy * no known allergies to drugs * ASA 1=2 patients

Exclusion criteria

* history of diabetes * history of chronic pain treatment * pregnancy

Design outcomes

Primary

Measure	Time frame	Description
Analgesic Consumption	1 day after surgery	Pethidine consumption (patient controlled analgesia procedure) was recorded

Secondary

Measure	Time frame	Description
Visual Analog Scale	1 day after surgery	Visual analog scale on rest and movement was recorded.
Haemodynamic Changes	During the surgery	Arterial blood pressure, heart rate, peripheral oxygen saturation

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026